摘要
目的探讨RRM1基因表达与晚期tN,细胞肺癌含吉西他滨化疗方案疗效的关系。方法有40例接受含吉西他滨方案化疗晚期非小细胞肺癌患者人组，采用分支DNA-液相芯片技术检测RRM1mRNA表达的水平，预测吉西他滨在晚期肺癌中的化疗疗效。结果RRM1低表达者23例f57．5％），高表达者17例（42．5％），低表达与高表达患者的化疗有效率、疾病进展时间分别为78．2％、12．4个月和35．2％、8．2个月，两组比较差异有统计学意义（P〈0．05）。结论RRM1基因表达水平可作为预测晚期非小细胞肺癌对含吉西他滨化疗方案的指标之一。
Objective To investigate the relationship between genetic polymorphisms of RRM 1 and survival of patients with advanced non-small cell lung cancer（NSCLC） treated with gemcitabine based chemotherapy.Methods 40 cases treated with gemcitabine chemotherapy in patients with advanced non-small cell lung cancer, the branch DNA- liquid chip detection of RRM1 mRNA expression level, curative effect of gemcitabine in advanced lung cancer prediction. Results 23 patients with low expression of RRM1 （ 57.5% ）, high expression in 17 cases （ 42.5% ）, and low expression in patients with high expression of chemotherapy efficiency, time to disease progression was 78.2%, 35.2%, 12.4 months and 8.2 months, with a significant difference between two groups （ P〈0.05 ）. Conclusion The expression of RRM1 gene could be used to predict the chemotherapy index of advanced non-small cell cancer with gemcitabine platinum.
出处
《国际医药卫生导报》
2013年第12期1763-1766,共4页
International Medicine and Health Guidance News
基金
广州市卫生局资助（201102A213009）
